RESEARCH TRIANGLE PARK – Michael Stocum has resigned as chief executive officer at Inviata, a clinical cancer genomics company with operations in the Triangle and U.K.
A search has begun for a replacement, the company said, in an announcement made earlier this week.
Stocum stepped down as CEO to pursue other interests, the company said.
“It has been a privilege leading Inivata as we grew from an academic spinout to our current stage of development over the past four years,” Stocum said in a statement. “The company is now entering its next stage of growth with an increasing focus on commercialisation and needs a CEO with a different set of skills.”
In the announcement, company Chairman Jeff Buchalter noted: “I would like to thank Mike for his significant contribution to Inivata and wish him well in his future endeavours. Inivata has developed a highly-sensitive liquid biopsy platform that positions it strongly in a fast-growing market. I look forward to the next phase of the Company’s development with considerable confidence.”
